More sensitive technology spurs proteomic and metabolomic biomarker identification, clinical use. (Complete article on page 21)
More sensitive technology spurs proteomic and metabolomic biomarker identification, clinical use. (Complete article on page 21)
Addressing the vital economic challenge of uncovering new critical quality attributes (CQAs), Paradigm4’s REVEALTM Analytical Development app enables data analysts…
The past few years have seen several flashy demonstrations of how artificial intelligence (AI) algorithms may transform biomedical research, particularly with respect to drug discovery.
Precision medicine is poised to transform healthcare, with biobanks being identified as a key enabler to bring it to fruition by 2030 by putting new, extended datasets at the disposal of pharmaceutical researchers and healthcare professionals. — by Marilyn Matz